NO314402B1 - Nye spiroimidazolinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem - Google Patents

Nye spiroimidazolinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem Download PDF

Info

Publication number: NO314402B1
Authority: NO; Norway
Prior art keywords: formula; compounds; compound; trans; pharmaceutically acceptable
Prior art date: 1998-12-18

Application number

NO19996285A

Other languages

English (en)

Norwegian (no)

Other versions

NO996285L (no

NO996285D0 (no

Inventor

Alex Cordi

Mark Millan

Adrian Newman-Tancredi

Mauricette Brocco

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-18

Filing date

1999-12-17

Publication date

2003-03-17

1999-12-17 Application filed by Servier Lab filed Critical Servier Lab

1999-12-17 Publication of NO996285D0 publication Critical patent/NO996285D0/no

2000-06-19 Publication of NO996285L publication Critical patent/NO996285L/no

2003-03-17 Publication of NO314402B1 publication Critical patent/NO314402B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 59
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims abstract description 6
238000000034 method Methods 0.000 title claims description 5
239000002253 acid Substances 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 12
125000003003 spiro group Chemical group 0.000 claims abstract description 12
-1 cyano, nitro, amino Chemical group 0.000 claims abstract description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 14
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 5
208000020401 Depressive disease Diseases 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 4
VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 claims description 3
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 3
OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 claims description 3
229910010084 LiAlH4 Inorganic materials 0.000 claims description 3
XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 claims description 3
239000012280 lithium aluminium hydride Substances 0.000 claims description 3
JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 claims description 3
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
206010033664 Panic attack Diseases 0.000 claims description 2
208000018737 Parkinson disease Diseases 0.000 claims description 2
201000001880 Sexual dysfunction Diseases 0.000 claims description 2
238000007059 Strecker synthesis reaction Methods 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
208000010877 cognitive disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
150000002462 imidazolines Chemical group 0.000 claims description 2
125000002636 imidazolinyl group Chemical group 0.000 claims description 2
208000001022 morbid obesity Diseases 0.000 claims description 2
208000019906 panic disease Diseases 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
208000019899 phobic disease Diseases 0.000 claims description 2
231100000872 sexual dysfunction Toxicity 0.000 claims description 2
239000007858 starting material Substances 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 1
125000003282 alkyl amino group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000004963 sulfonylalkyl group Chemical group 0.000 abstract 1
125000004001 thioalkyl group Chemical group 0.000 abstract 1
239000000243 solution Substances 0.000 description 22
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000011534 incubation Methods 0.000 description 9
238000002844 melting Methods 0.000 description 9
230000008018 melting Effects 0.000 description 9
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000000674 adrenergic antagonist Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000027455 binding Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000012417 linear regression Methods 0.000 description 3
238000005567 liquid scintillation counting Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000000407 monoamine reuptake Effects 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000000966 norepinephrine reuptake Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
XJLDYKIEURAVBW-UHFFFAOYSA-N Aethyl-heptyl-keton Natural products CCCCCCCC(=O)CC XJLDYKIEURAVBW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000001800 adrenalinergic effect Effects 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
210000005153 frontal cortex Anatomy 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
230000006461 physiological response Effects 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
230000000697 serotonin reuptake Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
LZSYGJNFCREHMD-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1Br LZSYGJNFCREHMD-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
WETRBJOSGIDJHQ-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C2=CC=CC=C2CCC=1CC1=NCCN1 WETRBJOSGIDJHQ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
UQABYHGXWYXDTK-UUOKFMHZSA-N GppNP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)NP(O)(O)=O)[C@@H](O)[C@H]1O UQABYHGXWYXDTK-UUOKFMHZSA-N 0.000 description 1
OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229950000323 napamezole Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
229950004211 nisoxetine Drugs 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Addiction (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19996285A 1998-12-18 1999-12-17 Nye spiroimidazolinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem NO314402B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9816000A FR2787450B1 (fr)	1998-12-18	1998-12-18	Nouveaux derives spiroimidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO996285D0 NO996285D0 (no)	1999-12-17
NO996285L NO996285L (no)	2000-06-19
NO314402B1 true NO314402B1 (no)	2003-03-17

Family

ID=9534134

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19996285A NO314402B1 (no)	1998-12-18	1999-12-17	Nye spiroimidazolinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem

Country Status (21)

Country	Link
US (1)	US6172097B1 (de)
EP (1)	EP1010694B1 (de)
JP (1)	JP3457241B2 (de)
KR (1)	KR100472522B1 (de)
CN (1)	CN1149201C (de)
AT (1)	ATE246680T1 (de)
AU (1)	AU760373B2 (de)
BR (1)	BR9905904A (de)
CA (1)	CA2292920C (de)
DE (1)	DE69910156T2 (de)
DK (1)	DK1010694T3 (de)
EA (1)	EA002979B1 (de)
ES (1)	ES2205741T3 (de)
FR (1)	FR2787450B1 (de)
HU (1)	HU225820B1 (de)
NO (1)	NO314402B1 (de)
NZ (1)	NZ501890A (de)
PL (1)	PL202368B1 (de)
PT (1)	PT1010694E (de)
SI (1)	SI1010694T1 (de)
ZA (1)	ZA997735B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6638981B2 (en)	2001-08-17	2003-10-28	Epicept Corporation	Topical compositions and methods for treating pain
EP2254420A4 (de)	2008-02-20	2012-02-15	Targia Pharmaceuticals	Zns-pharmazeutika und verfahren für ihre verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5017584A (en)	1984-12-20	1991-05-21	Sterling Drug Inc.	Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas
US6294185B1 (en) *	1993-03-12	2001-09-25	Auburn University	Monomeric and polymeric cyclic amine and N-halamine compounds
FR2707981B1 (fr) *	1993-07-20	1995-09-01	Adir	Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2707982B1 (fr) *	1993-07-20	1995-09-01	Adir	Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2709306B1 (fr) *	1993-07-20	1995-10-20	Adir	Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

1998
- 1998-12-18 FR FR9816000A patent/FR2787450B1/fr not_active Expired - Fee Related
1999
- 1999-12-16 JP JP35716799A patent/JP3457241B2/ja not_active Expired - Fee Related
- 1999-12-17 ZA ZA9907735A patent/ZA997735B/xx unknown
- 1999-12-17 EA EA199901049A patent/EA002979B1/ru not_active IP Right Cessation
- 1999-12-17 DK DK99403189T patent/DK1010694T3/da active
- 1999-12-17 ES ES99403189T patent/ES2205741T3/es not_active Expired - Lifetime
- 1999-12-17 BR BR9905904-5A patent/BR9905904A/pt not_active Application Discontinuation
- 1999-12-17 AU AU65291/99A patent/AU760373B2/en not_active Ceased
- 1999-12-17 PT PT99403189T patent/PT1010694E/pt unknown
- 1999-12-17 PL PL337265A patent/PL202368B1/pl not_active IP Right Cessation
- 1999-12-17 US US09/465,619 patent/US6172097B1/en not_active Expired - Fee Related
- 1999-12-17 CA CA002292920A patent/CA2292920C/fr not_active Expired - Fee Related
- 1999-12-17 DE DE69910156T patent/DE69910156T2/de not_active Expired - Lifetime
- 1999-12-17 NZ NZ501890A patent/NZ501890A/xx not_active IP Right Cessation
- 1999-12-17 HU HU9904629A patent/HU225820B1/hu not_active IP Right Cessation
- 1999-12-17 SI SI9930368T patent/SI1010694T1/xx unknown
- 1999-12-17 AT AT99403189T patent/ATE246680T1/de not_active IP Right Cessation
- 1999-12-17 NO NO19996285A patent/NO314402B1/no not_active IP Right Cessation
- 1999-12-17 EP EP99403189A patent/EP1010694B1/de not_active Expired - Lifetime
- 1999-12-17 CN CNB991278305A patent/CN1149201C/zh not_active Expired - Fee Related
- 1999-12-18 KR KR10-1999-0058931A patent/KR100472522B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR9905904A (pt)	2000-08-29
PL202368B1 (pl)	2009-06-30
NZ501890A (en)	2001-03-30
FR2787450A1 (fr)	2000-06-23
NO996285L (no)	2000-06-19
PT1010694E (pt)	2003-10-31
KR20000067830A (ko)	2000-11-25
ATE246680T1 (de)	2003-08-15
JP3457241B2 (ja)	2003-10-14
EP1010694B1 (de)	2003-08-06
HU9904629D0 (en)	2000-02-28
DE69910156D1 (de)	2003-09-11
EP1010694A2 (de)	2000-06-21
SI1010694T1 (en)	2003-12-31
US6172097B1 (en)	2001-01-09
KR100472522B1 (ko)	2005-03-07
NO996285D0 (no)	1999-12-17
CA2292920A1 (fr)	2000-06-18
CN1149201C (zh)	2004-05-12
ES2205741T3 (es)	2004-05-01
HK1029117A1 (en)	2001-03-23
HUP9904629A2 (hu)	2000-08-28
DE69910156T2 (de)	2004-06-09
HUP9904629A3 (en)	2000-12-28
DK1010694T3 (da)	2003-11-24
EP1010694A3 (de)	2000-07-26
CN1264704A (zh)	2000-08-30
AU6529199A (en)	2000-06-22
CA2292920C (fr)	2004-01-27
FR2787450B1 (fr)	2001-01-26
EA199901049A3 (ru)	2000-08-28
EA002979B1 (ru)	2002-12-26
EA199901049A2 (ru)	2000-08-28
HU225820B1 (en)	2007-10-29
AU760373B2 (en)	2003-05-15
PL337265A1 (en)	2000-06-19
ZA997735B (en)	2000-06-19
JP2000178257A (ja)	2000-06-27

Legal Events

Date	Code	Title	Description
2011-07-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
FI113262B (fi)	2004-03-31	Menetelmä N-propargyyli-1-aminoindaanin fluorattujen johdannaisten valmistamiseksi
US4818764A (en)	1989-04-04	Imidazoline derivative and method of treating depression therewith
WO2003010169A1 (en)	2003-02-06	Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene
RU2056418C1 (ru)	1996-03-20	Производные замещенного имидазолидин-2-она, способ их получения и фармацевтическая композиция
US5925665A (en)	1999-07-20	Imidazoline compounds
AU674080B2 (en)	1996-12-05	New benzospiroalkene compounds, process for preparing them and pharmaceutical compositions containing them
AU767856B2 (en)	2003-11-27	New imidazoline compounds, a process for their preparation and pharmaceutical compositions containing them
JP2012526077A (ja)	2012-10-25	新規イソキノリン誘導体
HU190983B (en)	1986-12-28	Process for preparing imidazole derivatives and pharmaceutical compositions containing such compounds
US6172097B1 (en)	2001-01-09	Spiro imidazoline compounds
DK172834B1 (da)	1999-08-09	Benzyldimethylsilylmethanaminer og farmaceutisk acceptable salte deraf
MXPA99011774A (en)	2000-07-01	New compounds of spyroimidazole
EP0382533B1 (de)	1993-01-27	Indol-Derivate
KR840002020B1 (ko)	1984-11-05	트랜스-4-페닐-1, 2, 3, 4-테트라하이드로-1-나프탈렌아민 유도체의 제조방법
KR19980701921A (ko)	1998-06-25	혈관 수축성 치환된 2,3-디하이드로-1,4-디옥시노피리딘
US20060160881A1 (en)	2006-07-20	Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan
JP3676110B2 (ja)	2005-07-27	新規ベンゾシクロブタン化合物、その製造法及びそれを含有する医薬組成物
NO318158B1 (no)	2005-02-07	Nye heterocykloalkylbenzocyklobutan- og heteroarylbenzocyklobutanforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
HK1002410B (en)	1998-08-21	Indole derivates